ECSP961751A - USE OF A 1 L AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE - Google Patents

USE OF A 1 L AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE

Info

Publication number
ECSP961751A
ECSP961751A ECSP961751A ECSP961751A EC SP961751 A ECSP961751 A EC SP961751A EC SP961751 A ECSP961751 A EC SP961751A EC SP961751 A ECSP961751 A EC SP961751A
Authority
EC
Ecuador
Prior art keywords
agonists
treatment
urinary incontinence
alpha
incontinence
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Franz Esser
Hisato Kitagawa
Ikunobu Muramatsu
Helmut Staehle
Sven Luettke
Shuji UCHIDA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP961751 priority Critical patent/ECSP961751A/en
Publication of ECSP961751A publication Critical patent/ECSP961751A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a la utilización de agonistas de alfa 1L para el tratamiento de la incontinencia urinaria.Refers to the use of alpha 1L agonists for the treatment of urinary incontinence.

ECSP961751 1996-04-18 1996-04-18 USE OF A 1 L AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE ECSP961751A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP961751 ECSP961751A (en) 1996-04-18 1996-04-18 USE OF A 1 L AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP961751 ECSP961751A (en) 1996-04-18 1996-04-18 USE OF A 1 L AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE

Publications (1)

Publication Number Publication Date
ECSP961751A true ECSP961751A (en) 1997-10-03

Family

ID=42042481

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP961751 ECSP961751A (en) 1996-04-18 1996-04-18 USE OF A 1 L AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE

Country Status (1)

Country Link
EC (1) ECSP961751A (en)

Similar Documents

Publication Publication Date Title
TR199701212T1 (en) Use of alpha IL-agonists for the treatment of urinary incontinence.
ES2055587T3 (en) THE USE OF SELECTIVE GABA-B AGONISTS AS ANTI-TUSSIVE AGENTS.
BR9902191A (en) Absorbent article
ES2154741T3 (en) USE OF CD23 UNION AGENTS IN THE TREATMENT OF AUTOIMMUNE DISEASES.
GT199600026A (en) ISOTIAZOLONES
ES2184127T3 (en) DERIVATIVES OF USEFUL ANTI-CONVULSIVE SULFAMATE FOR THE TREATMENT OF OBESITY.
ES2055197T3 (en) A COMPOSITION CONTAINING D-CYCLOSERINE AND D-ALANINE FOR THE INCREASE OF MEMORY AND THE LEARNING OR TREATMENT OF A COGNITIVE OR PSYCHOTIC DISORDER.
ES2138691T3 (en) PROCEDURE FOR THE OBTAINING OF DERIVATIVES OF N-ACIL-5-FLUOROCITIDINA.
BR9306683A (en) Aldehyde-cured proteinaceous adhesive
NO992470L (en) 2-amidazolinyl-amino-indole compounds useful as <alpha> -2-adrenoceptor agonists
AR016981A2 (en) SYNTHETIC POLYPEPTIDES
KR970702733A (en) COLLAGEN PREPARATION THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES
ES2145373T3 (en) PROCEDURE FOR THE DEVELOPMENT OF TRAMADOL RACEMATE.
BR9707078A (en) Body soap composition
ID22060A (en) COMPOUNDS OF 2-IMIDAZOLINYLAMINOBENZOKSAZOL USE AS ADRENOSEPTOR AGONISTS
ES2110661T3 (en) MODIFIED ELASTOMER POLYPROPYLENE.
ES1035958Y (en) DEVICE FOR THE CONTROL OF MALE INCONTINENCE.
BR0012006A (en) Method to prevent inflammation, autoimmune diseases and tumor growth, and use of substances that suppress ltbr-mediated activation
TR26931A (en) Use of molybdenum compounds in lacquer coagulation.
ES2174150T3 (en) PROCEDURE FOR OBTAINING 4-HYDROXIANILINS.
BR0016616A (en) Attenuated microorganisms for the treatment of infection
IL127930A0 (en) Verapamil as a medicament for the treatment of angina
BR0006240A (en) Composition, and, use of a microorganism of corineform bacteria
SU1540328A1 (en) HYDROGEN CORROSION STEEL INHIBITOR
PT1017377E (en) UTILIZATION OF 6,7-SUBSTITUTED 2-AMINOTETRALINS FOR THE TREATMENT OF CYLOCHINE-MEDIATED INFLAMMATORY CONDITIONS